Werewolf Therapeutics, Inc.

HOWL

NASDAQ

Healthcare

Biotechnology

Watertown, MA, US46 employeeswerewolftx.com

$1.00

+0.05(4.86%)

Mkt Cap $49M

$0.55

$2.19

52-Week Range

At a Glance

AI-generated

Werewolf Therapeutics' FY 2025 results reflect a company in a critical strategic transition, with operating and net losses narrowing to -$60.7M and -$60.8M, respectively, representing year-over-year improvements of 17.6% and 13.7%.

Revenue breakdown: Reportable Segment (100%).

8-K

Werewolf Therapeutics reported its fourth quarter and full year 2025 financial results, including a net loss of $8.4 million for Q4 2025 and $60.8 million for the full year. The company also announced it has initiated a process to explore strategic alternatives, including a potential sale, merger, or asset sale, and has engaged Piper Sandler as its exclusive financial advisor.

$49M

Market Cap

—

Revenue

-$78M

Net Income

Employees46

Fundamentals

How The Business Makes Money

Revenue by Segment

Reportable Segment100%($2M)

Activity

What Changed Recently

Impairment

Feb 12, 2026

Costs Associated with Exit or Disposal Activities. On February 9, 2026, the board of directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”) appr

Delisting

Feb 5, 2026

. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 4, 2026, Werewolf Therapeutics, Inc. (the “Co

Financial Results

Mar 26, 2026

in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as am

Other Event

Feb 23, 2026

Other Events. On February 24, 2026, Werewolf Therapeutics, Inc. issued a press release announcing that it plans to explore strategic alternatives and has engage

Peer Companies

Company	Price	Change	Market Cap	P/E
ACETAdicet Bio, Inc.	$6.98	+1.45%	$67M	-0.4
OSTXOS Therapies Incorporated	$1.37	+0.74%	$48M	—
LITSLite Strategy, Inc.	$1.13	+0.00%	$42M	-0.2
SPRBSpruce Biosciences, Inc.	$71.00	+2.11%	$41M	-1.2
NRXPNRx Pharmaceuticals, Inc.	$2.20	+1.85%	$38M	-1.0
INMBINmune Bio, Inc.	$1.21	-1.63%	$32M	-0.7
CUECue Biopharma, Inc.	$0.18	-11.20%	$14M	-1.1
OTLKOutlook Therapeutics, Inc...	$0.21	+2.38%	$9M	-0.2

Analyst View

Company Profile

CIK0001785530

ISINUS95075A1079

CUSIP95075A107

Phone617 952 0555

Address1030 Massachusetts Avenue, Watertown, MA, 02138, US

SEC EDGAR